Urologic Oncology: Seminars and Original Investigations
Volume 28, Issue 2 , Pages 189-194 , March 2010

Prevention of urinary bladder cancer in the FHIT knock-out mouse with Rofecoxib, a Cox-2 inhibitor

  • Domenico D'Arca, Ph.D.

      Affiliations

    • Department of Urology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA
    • Dipartimento di Scienze Biomediche, Sezione di Chimica Biologica, University of Modena and Reggio Emilia, Modena, Italy
    • These authors contributed equally to this work.
    • ,
  • James LeNoir, Ph.D.

      Affiliations

    • Department of Urology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA
    • These authors contributed equally to this work.
    • ,
  • Bernadette Wildemore, M.D.

      Affiliations

    • Department of Pathology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA
    • These authors contributed equally to this work.
    • ,
  • Fedra Gottardo, M.D.

      Affiliations

    • Department of Urology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA
    • These authors contributed equally to this work.
    • ,
  • Emma Bragantini, M.D.

      Affiliations

    • Department of Urology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA
    • Current address: Department of Pathology, Anatomic Pathology Unit, University of Verona, Verona.
    • ,
  • Dolores Shupp-Byrne, Ph.D.

      Affiliations

    • Department of Urology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA
    • ,
  • Nicola Zanesi, M.D.

      Affiliations

    • Department of Molecular Virology, Immunology, and Medical Genetics, Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210, USA
    • NZ is a Kimmel Scholar.
    • ,
  • Matteo Fassan, M.D.

      Affiliations

    • Department of Urology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA
    • Current address: Department of Diagnostic Sciences and Special Therapies, Pathology Unit, University of Padova, Padova.
    • ,
  • Carlo M. Croce, M.D.

      Affiliations

    • Department of Molecular Virology, Immunology, and Medical Genetics, Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210, USA
    • ,
  • Leonard G. Gomella, M.D.

      Affiliations

    • Department of Urology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA
    • ,
  • Raffaele Baffa, M.D.

      Affiliations

    • Department of Urology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA
    • Current address: Department of Translational Sciences, Research, MedImmune, Gaithersburg, MD.
    • Corresponding Author InformationCorresponding author. Tel.: +1-215-955-9072; fax: +1-215-503-2627

Received 13 June 2008 ,Revised 14 January 2009 ,Accepted 15 January 2009.

References 

  1. Kelloff GJ, Boone CW, Crowell JA, et al. Chemopreventive drug development: perspectives and progress. Cancer Epidemiol Biomarkers Prev. 1994;3:85–98
  2. Pereg D, Lishner M. Nonsteroidal anti-inflammatory drugs for the prevention and treatment of cancer. J Intern Med. 2005;258:115–123
  3. Dubois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. FASEB J. 1998;12:1063–1073
  4. Ziegler J. Early trials probe COX-2 inhibitors' cancer-fighting potential. J Natl Cancer Inst. 1999;91:1186–1187
  5. Chandrasekharan NV, Dai H, Roos KLT, et al. COX-3 a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression. PNAS. 2002;99:13926–13931
  6. Steele VE, Hawk ET, Viner JL, et al. Mechanisms and applications of non-steroidal anti-inflammatory drugs in the chemoprevention of cancer. Mutat Res. 2003;523/4:137–144
  7. Chan CC, Boyce S, Brideau C, et al. Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: A potent and orally active cyclooxygenase-2 inhibitor pharmacological and biochemical profiles. J Pharmacol Exp Ther. 1999;290:551–560
  8. Masferrer JL, Isakson PC, Seibert K. Cyclooxygenase-2 inhibitors: A new class of anti-inflammatory agents that spare the gastrointestinal tract. Gastroenterol Clin North Am. 1996;25:363–372
  9. Soslow RA, Dannenberg AJ, Rush D, et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer. 2000;89:2637–2645
  10. Fischer SM, Lo HH, Gordon GB, et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinog. 1999;25:231–240
  11. Tucker ON, Dannenberg AJ, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res. 1999;59:987–990
  12. Ristimaki A, Honkanen N, Jankala H, et al. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 1997;57:1276–1280
  13. Pruthi RS, Derksen E, Gaston K, et al. Rationale for use of cyclooxygenase-2 inhibitors in prevention and treatment of bladder cancer. Urology. 2004;64:637–642
  14. Gurocak S, Sozen S, Erdem O, et al. Relation between cyclooxygenase-2 expression and clinicopathologic parameters with patient prognosis in transitional cell carcinoma of the bladder. Urol Int. 2006;76:51–56
  15. Shirahama T. Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder. Clin Cancer Res. 2000;6:2424–2430
  16. Wadhwa P, Goswami AK, Joshi K, et al. Cyclooxygenase-2 expression increases with the stage and grade in transitional cell carcinoma of the urinary bladder. Int Urol Nephrol. 2005;37:47–53
  17. Kim SI, Kwon SM, Kim YS, Hong SJ. Association of cyclooxygenase-2 expression with prognosis of stage T1 grade 3 bladder cancer. Urology. 2002;60:816–821
  18. Kitayama W, Denda A, Okajima E, et al. Increased expression of cyclooxygenase-2 protein in rat urinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl) nitrosamine. Carcinogenesis. 1999;20:2305–2310
  19. Hattori K, Iida K, Joraku A, et al. Chemopreventive effects of cyclooxygenase-2 inhibitor and epidermal growth factor-receptor kinase inhibitor on rat urinary bladder carcinogenesis. BJU Int. 2006;97:640–643
  20. Grubbs CJ, Lubet RA, Koki AT, et al. Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res. 2000;60:5599–5602
  21. Okajima E, Denda A, Ozono S, et al. Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the development of rat urinary bladder carcinomas initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine. Cancer Res. 1998;58:3028–3031
  22. Lubet RA, Huebner K, Fong LY, et al. 4-Hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers in mice: Characterization of FHIT and survivin expression and chemopreventive effects of indomethacin. Carcinogenesis. 2005;26:571–578
  23. Vecchione A, Sevignani C, Giarnieri E, et al. Inactivation of the FHIT gene favors bladder cancer development. Clin Cancer Res. 2004;10:7607–7612
  24. Ohta M, Inoue H, Cotticelli MG, et al. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell. 1996;84:587–597
  25. Baffa R, Gomella LG, Vecchione A, et al. Loss of FHIT expression in transitional cell carcinoma of the urinary bladder. Am J Pathol. 2000;156:419–424
  26. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66
  27. Baffa R, Letko J, McClung C, et al. Molecular genetics of bladder cancer: Targets for diagnosis and therapy. J Exp Clin Cancer Res. 2006;25:145–160
  28. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. NEJM. 2000;343:1520–1528
  29. Iliopoulos D, Guler G, Han SY, et al. Fragile genes as biomarkers: Epigenetic control of WWOX and FHIT in lung, breast and bladder cancer. Oncogene. 2005;24:1625–1633
  30. Ristimaki A, Nieminen O, Saukkonen K, et al. Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder. Am J Pathol. 2001;158:849–853
  31. Hilmy M, Campbell R, Bartlett JM, et al. The relationship between the systemic inflammatory response, tumor proliferative activity, T-lymphocytic infiltration and COX-2 expression and survival in patients with transitional cell carcinoma of the urinary bladder. Br J Cancer. 2006;95:1234–1238
  32. Skopelitou AS, Gloustianou G, Bai M, et al. FHIT gene expression in human urinary bladder transitional cell carcinomas. In Vivo. 2001;15:169–173
  33. Gutiérrez MI, Siraj AK, Khaled H, et al. CpG island methylation in Schistosoma- and non-Schistosoma-associated bladder cancer. Mod Pathol. 2004;17:1268–1274
  34. Dumon KR, Ishii H, Fong LY, et al. FHIT gene therapy prevents tumor development in FHIT-deficient mice. Proc Natl Acad Sci USA. 2001;98:3346–3351
  35. Fong LY, Fidanza V, Zanesi N, et al. Muir-Torre-like syndrome in FHIT-deficient mice. Proc Natl Acad Sci USA. 2000;97:4742–4747

☆ This work was supported by a Merck and Co., Inc. Medical School grant.

PII: S1078-1439(09)00008-8

doi: 10.1016/j.urolonc.2009.01.016

Urologic Oncology: Seminars and Original Investigations
Volume 28, Issue 2 , Pages 189-194 , March 2010

Article Tools

* Image Usage & Resolution